Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -91.75% is 43% above its 5-year average of -161.34%, near the high end of its 5-year range (-728.36%–-91.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 46.96% above its 12-month average of -172.98%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -91.75%.
RETURN ON EQUITY (ROE)
-91.75%
RETURN ON EQUITY (ROE) AVG TTM
-172.98%
RETURN ON EQUITY (ROE) AVG 3Y
-288.99%
RETURN ON EQUITY (ROE) AVG 5Y
-161.34%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+46.96%
CURRENT VS 3Y AVG
+68.25%
CURRENT VS 5Y AVG
+43.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.16%
median of 398 covered companies
CURRENT VS SECTOR MEDIAN
-146.92%
vs the sector median at left
CNS Pharmaceuticals, Inc.
Market Cap
$7.75M
Return on Equity (ROE)
-91.75%
TTM Avg
-172.98%
3Y Avg
-288.99%
5Y Avg
-161.34%
Market Cap
$7.77M
Return on Equity (ROE)
-618.74%
TTM Avg
149.09%
3Y Avg
4.64%
5Y Avg
-24.92%
Market Cap
$7.31M
Return on Equity (ROE)
-1168.44%
TTM Avg
-606.51%
3Y Avg
-330.90%
5Y Avg
-270.23%
Market Cap
$8.37M
Return on Equity (ROE)
-31.99%
TTM Avg
-84.19%
3Y Avg
-171.49%
5Y Avg
-138.23%
Market Cap
$7.03M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
Market Cap
$6.88M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
Market Cap
$6.76M
Return on Equity (ROE)
-108.00%
TTM Avg
-445.77%
3Y Avg
-254.63%
5Y Avg
-239.85%
Market Cap
$6.74M
Return on Equity (ROE)
-54.09%
TTM Avg
-388.62%
3Y Avg
-105.04%
5Y Avg
-44.72%
Market Cap
$8.76M
Return on Equity (ROE)
-7.36%
TTM Avg
-85.10%
3Y Avg
-73.72%
5Y Avg
-96.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.75M | -91.75% | -172.98% | -288.99% | -161.34% |
| GT Biopharma, Inc. (GTBP)vs › | $7.77M | -618.74% | 149.09% | 4.64% | -24.92% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -1168.44% | -606.51% | -330.90% | -270.23% |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.37M | -31.99% | -84.19% | -171.49% | -138.23% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | -218.65% | -54.74% | -35.36% | -35.36% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -370.16% | -148.31% | -87.53% | -43.20% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -108.00% | -445.77% | -254.63% | -239.85% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -54.09% | -388.62% | -105.04% | -44.72% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.76M | -7.36% | -85.10% | -73.72% | -96.61% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -227.37% | -118.13% | -87.25% | -55.09% |
ROE
-91.8%
ROA
-76.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -91.75% |
| 2025-12-31 | -350.48% |
| 2025-09-30 | -131.90% |
| 2025-06-30 | -117.78% |
| 2025-03-31 | -142.34% |
| 2024-12-31 | -240.55% |
| 2024-09-30 | -508.80% |
| 2023-06-30 | -728.36% |
| 2023-03-31 | -498.93% |
| 2022-12-31 | -192.33% |
| 2022-09-30 | -154.07% |
| 2022-06-30 | -115.65% |
| 2022-03-31 | -91.71% |
| 2021-12-31 | -211.97% |
| 2021-09-30 | -156.55% |
| 2021-06-30 | -100.28% |
| 2021-03-31 | -98.76% |
| 2020-12-31 | -67.81% |
| 2020-09-30 | -362.92% |
| 2020-06-30 | -206.09% |
| 2020-03-31 | -95.89% |
| 2019-12-31 | -51.01% |
